Abstract:Objective: Acute ischemic stroke (AIS) is characterized by high rates of morbidity, disability, mortality, and recurrence, often leaving patients with varying degrees of sequelae. Symptomatic intracranial atherosclerotic stenosis (sICAS) is a significant contributor to AIS pathogenesis and recurrence. The formation and progression of sICAS are influenced by pathways such as lipid metabolism and inflammatory response. Given its high risk of clinical recurrence, timely assessment of intracranial vascular stenosis in AIS is crucial for diagnosing sICAS, treating stroke, and preventing stroke recurrence. Methods: Fourteen AIS patients were divided into stenosis and control groups based on the presence or absence of intracranial vessel stenosis. Initially, 4D Label-free proteome quantification technology was employed for mass spectrometry analysis to identify differential proteins between the groups. Subsequently, functional enrichment analysis, including GO classification, KEGG pathway, and Domain, revealed trends related to differential proteins. The STRING (v.11.5) protein interaction network database was used to identify differential protein interactions and target proteins. Finally, parallel reaction monitoring (PRM) validated the selected target proteins. Results: Mass spectrometry identified 1,096 proteins, with 991 being quantitatively comparable. Using a p-value <0.05 and differential expression change thresholds of >1.3 for significant up-regulation and < 1/1.3 for significant down-regulation, 46 differential proteins were identified: 24 significantly up-regulated and 22 significantly down-regulated. PRM experiments validated five proteins related to lipid metabolism and inflammatory response: namely alpha-2-macroglobulin (A2M), lipopolysaccharide-binding protein (LBP), cathepsin G (CTSG), cystatin (CST)3, and fatty acid-binding protein (FABP)1. Conclusion: The detection of changes in these five proteins in AIS patients can aid in the diagnosis of sICAS, inform stroke treatment, and assist in preventing stroke recurrence. Moreover, it can contribute to the development of drugs for preventing AIS recurrence by integrating traditional Chinese and Western medicine.

Markers of Brain Injury and Acute Ischemic Stroke

Imaging Markers in Acute Phase of Stroke: Implications for Prognosis

Network-Based Approach to Identify Potential Targets and Drugs That Promote Neuroprotection and Neurorepair in Acute Ischemic Stroke

Cerebrospinal Fluid Biomarkers for Diagnosis and the Prognostication of Acute Ischemic Stroke: A Systematic Review

Metabolomic Characterization of Acute Ischemic Stroke Facilitates Metabolomic Biomarker Discovery

Biomarkers and the outcomes of ischemic stroke

Biomarkers for acute diagnosis and management of stroke in neurointensive care units

Body fluids biomarkers associated with prognosis of acute ischemic stroke: progress and prospects

Molecular biomarkers in stroke diagnosis and prognosis

Ischemic stroke biomarkers in blood

Blood biomarkers in the early stage of cerebral ischemia

Acute ischemic stroke biomarkers: a new era with diagnostic promise?

Diagnostic Performance of Circulating MicroRNAs in Acute Ischemic Stroke

Advances in development of biomarkers for brain damage and ischemia

Blood-based protein biomarkers during the acute ischemic stroke treatment window: a systematic review

Neuronal plasma biomarkers in acute ischemic stroke

Multi-Level Biomarkers for Early Diagnosis of Ischaemic Stroke: A Systematic Review and Meta-Analysis

Identification of Site-Specific Stroke Biomarker Candidates by Laser Capture Microdissection and Labeled Reference Peptide

Biomarker study of symptomatic intracranial atherosclerotic stenosis in patients with acute ischemic stroke

Protein Biomarkers for Traumatic and Ischemic Brain Injury: From Bench to Bedside

Early Warning of Ischemic Stroke Based on Atherosclerosis Index Combined With Serum Markers